Trial Profile
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors Harboring Either a ROS1 or NTRK Fusion Gene
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Taletrectinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 31 Mar 2023 According to an AnHeart Therapeutics media release, the company presented updated results from a pooled analysis including patients from this, NCT04395677, and NCT02279433 trials, in an oral presentation at the European Lung Cancer Congress (ELCC) 2023.
- 09 May 2022 Status changed from active, no longer recruiting to completed.
- 12 Jan 2021 Planned End Date changed from 1 Mar 2022 to 1 Apr 2022.